(Q35773857)

10 August 2017

1 reference

title

The development of proteasome inhibitors as anticancer drugs (English)

1 reference

10 August 2017

Julian Adams

1

1 reference

10 August 2017

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

417-421

1 reference

Development of the proteasome inhibitor PS-341.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Proteasome inhibition: a novel approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

The proteasome: structure, function, and role in the cell

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

The proteasome: a novel target for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Activation of the cell death program by inhibition of proteasome function

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Preferential induction of apoptosis for primary human leukemic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

NF-kappaB in cancer: from innocent bystander to major culprit

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

Regulation of apoptosis proteins in cancer cells by ubiquitin

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900120-5

7 January 2021

10.1016/S1535-6108(04)00120-5

Identifiers

DOI

1 reference

10 August 2017

1 reference